2018 ACR/ARHP Annual Meeting

October 19-24, 2018. Chicago, IL.

View by Number View by Title View Sessions

View by Date

Abstract Number: 630

Is Treatment Adherence of RA Patients to Injectable MTX Influenced By Previous MTX Route of Administration?
Abstract Number: 631

A Self-Determination Theory Based Intervention to Promote Autonomous Motivation for, and Engagement in Physical Activity in Rheumatoid Arthritis: Theoretical Process Evaluation of a Randomised Controlled Trial
Abstract Number: 632

Interpretation of Symptoms Should Take into Account Gender in Psoriatic Arthritis: An Analysis of 451 Patients
Abstract Number: 633

The Effect of Guselkumab on Dactylitis: Results from a Phase 2 Study in Patients with Active Psoriatic Arthritis
Abstract Number: 634

Spinal Mobility Measures Allow Discrimination of Subgroups of Different Activity and Severity in Early Axial Spondyloarthritis
Abstract Number: 635

Measuring Spinal Mobility over Time in Early Axial Spondyloarthritis: Can We Do It Reliably?
Abstract Number: 636

Remission/Low Disease Activity Is a Reasonable Treatment Target in Psa: Results from a Routine Care European Cohort of Psa Patients Treated with Ustekinumab or TNF Inhibitors
Abstract Number: 637

How to Define Remission and Low Disease Activity in Psoriatic Arthritis? an Analysis of 419 Patients with a Double Perspective, Based on Composite Scores and Patients’ and Physicians’ Perspectives
Abstract Number: 638

Diagnostic Delay and Associated Factors in Axial Spondyloarthritis across Europe. Results from the European Map of Axial Spondyloarthritis Survey
Abstract Number: 639

Is a Primary Good Response to Nsaids Predictive of the Subsequent Response to the First TNF Inhibitor in Patients with Early Axial Spondyloarthritis ?
Abstract Number: 640

Increasing Rates of Arthroplasty for Psoriatic Arthritis in the United Kingdom between 1995 and 2010
Abstract Number: 641

Construct Validity of the Swollen and Tender Joint Counts for the Measurement of MSK Disease Activity in Psoriatic Arthritis
Abstract Number: 642

Cost of Illness Analysis before and after Initiation of Tumour Necrosis Factor α Inhibitors in Patients with Axial Spondyloarthritis
Abstract Number: 643

Remission in Psoriatic Arthritis: Definition and Predictors
Abstract Number: 644

Influence of Inflammation and Structural Damage on Global Functioning in Patients with Axial Spondyloarthritis – Using the ASAS Health Index in Routine Care

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].